VOR – vor biopharma inc. (US:NASDAQ)
Stock Stats
News
Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors
Vor Biopharma (NASDAQ:VOR) had its price target lowered by analysts at JPMorgan Chase & Co. from $43.00 to $40.00. They now have an "overweight" rating on the stock.
Vor Biopharma (NASDAQ:VOR) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.
Vor Bio Announces $150 Million Private Placement
Vor Biopharma (VOR): Valuation Check After Positive Telitacicept Phase 3 Data and Upbeat JPMorgan Coverage [Yahoo! Finance]
Form SCHEDULE 13D Vor Biopharma Inc. Filed by: ForGrowth III PA B.V.
Form 4 Vor Biopharma Inc. For: Dec 18 Filed by: Kolchinsky Peter
Form 4 Vor Biopharma Inc. For: Dec 18 Filed by: Joustra Wouter
Form 4 Vor Biopharma Inc. For: Dec 18 Filed by: Levin Andrew David
Form 3 Vor Biopharma Inc. For: Dec 18 Filed by: Joustra Wouter
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.